Skip directly to content

How the Study Worked

 

Inspired to Be Informed

 

Clinical Study Results: How the Study Worked

The AROMASIN® (exemestane tablets) Intergroup Exemestane Study (IES) involved 4,724 women past menopause who were on tamoxifen.

After 2 to 3 years on tamoxifen, 2,352 of the women were randomly chosen to switch to AROMASIN and 2,372 remained on tamoxifen.

The women who were randomized to AROMASIN were compared with the women who stayed on tamoxifen.

A comparison took place almost 3 years (34.5 months) after the women were assigned to different groups. There was an additional follow-up after almost 5 years (52.4 months)—about 25 months after tamoxifen or AROMASIN treatment ended.

Most women received a total of 5 years of adjuvant treatment. Adjuvant treatment for breast cancer is a treatment given after primary surgery, radiation, hormonal therapy, chemotherapy, or a combination of treatments.

Study participants

Postmenopausal women who took part in the AROMASIN IES, including women who had:

  • Estrogen-receptor positive breast cancer—breast cancer that needs the hormone estrogen to grow
  • Progesterone-positive breast cancer—breast cancer that needs the hormone progesterone to grow
  • Node-positive breast cancer—breast cancer that has spread to the surrounding lymph nodes
  • Node-negative breast cancer—breast cancer that has not spread to the surrounding lymph nodes
  • Chemotherapy treatment
  • No chemotherapy treatment
  • Radiation treatment
  • No radiation treatment